Avalo Therapeutics (AVTX)
Avalo Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
12.0M
Short interest
settlement 2026-10-15
13.0
Days to cover
+4.2 days vs prior
55.6%
Short share of volume
2026-11-02
188
Fails to deliver
settlement 2026-10-02
Thu 5 Nov
Next earnings
estimated date
-$1.9M
Insider flow, 90 days
0 buys, 9 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in AVTX is 11,963,625 shares, down 962,244 shares over the last month. Over the last 48 readings it ranged from 5,218 shares (29 November 2024) to 13,092,767 shares (14 August 2026). The latest reading sits at the top of that range. At the reported average volume of 920K shares a day that is 13.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/avtx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 11,963,625 | +4.9% | 919,676 | 13.01 |
| 2026-09-30 | 11,405,304 | -11.8% | 1,296,416 | 8.80 |
| 2026-09-15 | 12,925,869 | +4.3% | 976,376 | 13.24 |
| 2026-08-31 | 12,387,012 | -5.4% | 816,596 | 15.17 |
| 2026-08-14 | 13,092,767 | +1.1% | 647,143 | 20.23 |
| 2026-07-31 | 12,950,314 | +2.1% | 900,454 | 14.38 |
| 2026-07-15 | 12,679,040 | +3.0% | 1,186,742 | 10.68 |
| 2026-06-30 | 12,307,967 | +66.0% | 2,887,428 | 4.26 |
| 2026-06-15 | 7,413,562 | +16.2% | 1,340,030 | 5.53 |
| 2026-05-29 | 6,382,270 | +2.0% | 1,464,002 | 4.36 |
| 2026-05-15 | 6,254,061 | +9.1% | 3,938,711 | 1.59 |
| 2026-04-30 | 5,733,586 | +9.5% | 708,216 | 8.10 |
| 2026-04-15 | 5,237,740 | -5.5% | 855,154 | 6.12 |
| 2026-03-31 | 5,542,400 | +35.5% | 892,659 | 6.21 |
| 2026-03-13 | 4,089,262 | +11.1% | 701,975 | 5.83 |
| 2026-02-27 | 3,681,926 | +2.4% | 510,549 | 7.21 |
| 2026-02-13 | 3,597,176 | +13.0% | 381,153 | 9.44 |
| 2026-01-30 | 3,183,754 | +6.8% | 391,774 | 8.13 |
| 2026-01-15 | 2,979,688 | +16.0% | 293,109 | 10.17 |
| 2025-12-31 | 2,568,740 | +38.2% | 339,981 | 7.56 |
| 2025-12-15 | 1,858,418 | +0.5% | 311,900 | 5.96 |
| 2025-11-28 | 1,848,452 | +0.5% | 353,682 | 5.23 |
| 2025-11-14 | 1,840,260 | +36.8% | 380,014 | 4.84 |
| 2025-10-31 | 1,345,096 | +3.3% | 411,674 | 3.27 |
| 2025-10-15 | 1,302,301 | +4.8% | 322,356 | 4.04 |
| 2025-09-30 | 1,242,948 | +513.9% | 618,519 | 2.01 |
| 2025-09-15 | 202,456 | +263.9% | 204,942 | 1.00 |
| 2025-08-29 | 55,637 | -38.4% | 129,871 | 1.00 |
| 2025-08-15 | 90,242 | +117.5% | 457,427 | 1.00 |
| 2025-07-31 | 41,492 | -74.7% | 207,682 | 1.00 |
| 2025-07-15 | 164,125 | +38.1% | 86,106 | 1.91 |
| 2025-06-30 | 118,829 | +41.8% | 76,377 | 1.56 |
| 2025-06-13 | 83,831 | +78.7% | 128,964 | 1.00 |
| 2025-05-30 | 46,915 | -45.8% | 67,617 | 1.00 |
| 2025-05-15 | 86,488 | +90.1% | 53,555 | 1.61 |
| 2025-04-30 | 45,497 | -54.7% | 51,248 | 1.00 |
| 2025-04-15 | 100,390 | -13.3% | 66,002 | 1.52 |
| 2025-03-31 | 115,733 | +20.4% | 58,337 | 1.98 |
| 2025-03-14 | 96,156 | +6.1% | 158,867 | 1.00 |
| 2025-02-28 | 90,618 | +19.3% | 48,630 | 1.86 |
| 2025-02-14 | 75,986 | +75.6% | 28,595 | 2.66 |
| 2025-01-31 | 43,263 | -22.5% | 78,818 | 1.00 |
| 2025-01-15 | 55,830 | +177.1% | 84,279 | 1.00 |
| 2024-12-31 | 20,145 | -12.1% | 173,089 | 1.00 |
| 2024-12-13 | 22,916 | +339.2% | 111,960 | 1.00 |
| 2024-11-29 | 5,218 | -46.6% | 54,619 | 1.00 |
| 2024-11-15 | 9,775 | -2.8% | 70,272 | 1.00 |
| 2024-10-31 | 10,057 | -79.6% | 44,079 | 1.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of AVTX volume is 55.6%, up 23.3 points over the last five sessions. Over the last 30 readings it ranged from 15.4% (27 October 2026) to 82.5% (8 October 2026). The latest reading is 3.5 points above the 30-session average of 52.1%, on 669K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 372K | 669K | 55.6% | 0 |
| 2026-10-30 | 446K | 706K | 63.1% | 0 |
| 2026-10-29 | 283K | 750K | 37.8% | 100 |
| 2026-10-28 | 262K | 727K | 36.0% | 0 |
| 2026-10-27 | 160K | 1.0M | 15.4% | 0 |
| 2026-10-26 | 252K | 781K | 32.3% | 3,252 |
| 2026-10-23 | 380K | 2.3M | 16.8% | 8,369 |
| 2026-10-22 | 2.8M | 13.7M | 20.6% | 40,773 |
| 2026-10-21 | 205K | 335K | 61.0% | 0 |
| 2026-10-20 | 192K | 577K | 33.3% | 0 |
| 2026-10-19 | 356K | 696K | 51.2% | 0 |
| 2026-10-16 | 167K | 338K | 49.6% | 0 |
| 2026-10-15 | 172K | 319K | 53.8% | 0 |
| 2026-10-14 | 349K | 515K | 67.8% | 0 |
| 2026-10-13 | 518K | 761K | 68.0% | 11 |
| 2026-10-12 | 131K | 214K | 61.1% | 0 |
| 2026-10-09 | 109K | 150K | 72.6% | 0 |
| 2026-10-08 | 178K | 216K | 82.5% | 0 |
| 2026-10-07 | 145K | 195K | 74.3% | 0 |
| 2026-10-06 | 200K | 339K | 59.0% | 409 |
| 2026-10-05 | 133K | 209K | 63.9% | 1 |
| 2026-10-02 | 195K | 259K | 75.4% | 0 |
| 2026-10-01 | 231K | 372K | 62.0% | 0 |
| 2026-09-30 | 312K | 608K | 51.4% | 0 |
| 2026-09-29 | 244K | 493K | 49.5% | 0 |
| 2026-09-28 | 106K | 331K | 32.2% | 0 |
| 2026-09-25 | 242K | 624K | 38.8% | 0 |
| 2026-09-24 | 393K | 791K | 49.7% | 0 |
| 2026-09-23 | 386K | 501K | 77.0% | 0 |
| 2026-09-22 | 117K | 225K | 52.1% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 2 October 2026, the fails-to-deliver balance in AVTX is 188 shares, up 90 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (27 July 2026) to 98,952 shares (26 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-02 | 188 | $14.95 | $3K |
| 2026-09-24 | 98 | $15.30 | $1K |
| 2026-09-23 | 734 | $16.51 | $12K |
| 2026-09-21 | 38,686 | $16.57 | $641K |
| 2026-09-16 | 36,351 | $16.07 | $584K |
| 2026-09-15 | 77,994 | $16.18 | $1.3M |
| 2026-09-04 | 1,793 | $19.00 | $34K |
| 2026-09-03 | 1,788 | $19.34 | $35K |
| 2026-08-31 | 100 | $19.59 | $2K |
| 2026-08-27 | 237 | $20.55 | $5K |
| 2026-08-26 | 98,952 | $19.74 | $2.0M |
| 2026-08-25 | 122 | $19.27 | $2K |
| 2026-08-24 | 1,016 | $19.83 | $20K |
| 2026-08-11 | 11,652 | $19.77 | $230K |
| 2026-08-07 | 2,026 | $18.70 | $38K |
| 2026-08-04 | 269 | $18.05 | $5K |
| 2026-07-31 | 1 | $19.39 | $19 |
| 2026-07-29 | 1,231 | $19.52 | $24K |
| 2026-07-27 | 1 | $18.44 | $18 |
| 2026-07-23 | 810 | $18.15 | $15K |
| 2026-07-21 | 1,593 | $18.21 | $29K |
| 2026-07-20 | 19,349 | $19.37 | $375K |
| 2026-07-17 | 591 | $17.88 | $11K |
| 2026-07-16 | 803 | $18.55 | $15K |
| 2026-07-15 | 13,682 | $18.42 | $252K |
| 2026-07-13 | 610 | $19.21 | $12K |
| 2026-07-09 | 1,206 | $19.21 | $23K |
| 2026-07-06 | 603 | $18.84 | $11K |
| 2026-07-02 | 16,411 | $17.29 | $284K |
| 2026-07-01 | 301 | $18.48 | $6K |
Insider trades
SEC Form 4, newest first. JSONInsiders at AVTX reported 9 open-market sells worth $1.9M in the last 90 days and no open-market buys. Latest filing: Sullivan Christopher Ryan (Chief Financial Officer) on 2026-09-16.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-16 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 12K | $16.33 | $202K | 40K |
| 2026-09-16 | Sullivan Christopher Ryan | Chief Financial Officer | Exercise or conversion | 12K | $9.88 | $122K | 52K |
| 2026-09-10 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 10K | $17.62 | $179K | 40K |
| 2026-09-10 | Sullivan Christopher Ryan | Chief Financial Officer | Exercise or conversion | 10K | $8.04 | $82K | 50K |
| 2026-08-28 | Doyle Mittie | Chief Medical Officer | Sell | 679 | $20.00 | $14K | 52K |
| 2026-08-28 | Doyle Mittie | Chief Medical Officer | Exercise or conversion | 679 | $8.04 | $5K | 52K |
| 2026-08-18 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 31K | $20.05 | $622K | 40K |
| 2026-08-18 | Sullivan Christopher Ryan | Chief Financial Officer | Exercise or conversion | 31K | $9.88 | $307K | 71K |
| 2026-08-17 | Doyle Mittie | Chief Medical Officer | Sell | 1K | $20.00 | $20K | 52K |
| 2026-08-17 | Doyle Mittie | Chief Medical Officer | Exercise or conversion | 1K | $12.65 | $13K | 53K |
| 2026-08-17 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 4K | $19.94 | $75K | 40K |
| 2026-08-17 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 38K | $19.85 | $753K | 44K |
| 2026-08-17 | Sullivan Christopher Ryan | Chief Financial Officer | Exercise or conversion | 3K | $9.88 | $28K | 82K |
| 2026-08-17 | Sullivan Christopher Ryan | Chief Financial Officer | Exercise or conversion | 38K | $9.88 | $375K | 79K |
| 2026-08-11 | Riley Jennifer | Chief Strategy Officer | Sell | 3K | $19.59 | $52K | 37K |
| 2026-08-10 | Doyle Mittie | Chief Medical Officer | Sell | 679 | $20.00 | $14K | 52K |
| 2026-08-10 | Doyle Mittie | Chief Medical Officer | Exercise or conversion | 679 | $8.04 | $5K | 52K |
| 2026-07-27 | Doyle Mittie | Chief Medical Officer | Sell | 1K | $20.00 | $20K | 52K |
| 2026-07-27 | Doyle Mittie | Chief Medical Officer | Exercise or conversion | 1K | $12.65 | $13K | 53K |
| 2026-06-30 | Doyle Mittie | Chief Medical Officer | Sell | 5K | $20.00 | $93K | 52K |
| 2026-06-30 | Doyle Mittie | Chief Medical Officer | Exercise or conversion | 2K | $8.04 | $14K | 56K |
| 2026-06-30 | Doyle Mittie | Chief Medical Officer | Exercise or conversion | 3K | $12.65 | $36K | 55K |
| 2026-06-23 | Doyle Mittie | Chief Medical Officer | Sell | 1K | $18.00 | $26K | 52K |
| 2026-06-23 | Doyle Mittie | Chief Medical Officer | Exercise or conversion | 1K | $8.04 | $12K | 53K |
| 2026-06-10 | Riley Jennifer | Chief Strategy Officer | Tax withholding | 588 | $13.10 | $8K | 40K |
| 2026-06-10 | Doyle Mittie | Chief Medical Officer | Tax withholding | 1K | $13.10 | $14K | 52K |
| 2026-06-10 | Sullivan Christopher Ryan | Chief Financial Officer | Tax withholding | 138 | $13.10 | $2K | 41K |
| 2026-06-10 | VARKI PAUL | Chief Legal Officer | Tax withholding | 1K | $13.10 | $14K | 33K |
| 2026-05-28 | Doyle Mittie | Chief Medical Officer | Sell | 679 | $16.00 | $11K | 47K |
| 2026-05-28 | Doyle Mittie | Chief Medical Officer | Exercise or conversion | 679 | $8.04 | $5K | 48K |
| 2026-05-21 | Riley Jennifer | Chief Strategy Officer | Grant | 34K | $0.00 | $0 | 37K |
| 2026-05-21 | Doyle Mittie | Chief Medical Officer | Grant | 44K | $0.00 | $0 | 47K |
| 2026-05-21 | Sullivan Christopher Ryan | Chief Financial Officer | Grant | 40K | $0.00 | $0 | 40K |
| 2026-05-21 | VARKI PAUL | Chief Legal Officer | Grant | 24K | $0.00 | $0 | 28K |
| 2026-05-21 | NEIL GARRY ARTHUR | Chief Executive Officer | Grant | 100K | $0.00 | $0 | 190K |
| 2026-05-15 | Doyle Mittie | Chief Medical Officer | Sell | 3K | $18.76 | $56K | 4K |
| 2026-05-15 | Doyle Mittie | Chief Medical Officer | Exercise or conversion | 3K | $12.65 | $38K | 7K |
| 2026-05-07 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 19K | $24.12 | $449K | 423 |
| 2026-05-07 | Sullivan Christopher Ryan | Chief Financial Officer | Exercise or conversion | 19K | $9.88 | $184K | 19K |
| 2026-05-06 | Doyle Mittie | Chief Medical Officer | Sell | 10K | $22.88 | $230K | 4K |
| 2026-05-06 | Doyle Mittie | Chief Medical Officer | Sell | 19K | $22.41 | $426K | 14K |
| 2026-05-06 | Doyle Mittie | Chief Medical Officer | Sell | 45K | $21.20 | $953K | 33K |
| 2026-05-06 | Doyle Mittie | Chief Medical Officer | Sell | 5K | $19.65 | $98K | 78K |
| 2026-05-06 | Doyle Mittie | Chief Medical Officer | Sell | 28K | $18.03 | $496K | 83K |
| 2026-05-06 | Doyle Mittie | Chief Medical Officer | Exercise or conversion | 29K | $8.04 | $230K | 110K |
| 2026-05-06 | Doyle Mittie | Chief Medical Officer | Exercise or conversion | 78K | $12.65 | $985K | 82K |
| 2026-05-06 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 9K | $22.57 | $201K | 423 |
| 2026-05-06 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 9K | $21.37 | $197K | 9K |
| 2026-05-06 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 3K | $20.76 | $56K | 19K |
| 2026-05-06 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 12K | $19.28 | $238K | 21K |
| 2026-05-06 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 14K | $18.55 | $257K | 34K |
| 2026-05-06 | Sullivan Christopher Ryan | Chief Financial Officer | Exercise or conversion | 47K | $8.04 | $378K | 47K |
| 2026-05-06 | Chan Mitchell | Director | Sell | 3K | $22.88 | $72K | 3K |
| 2026-05-06 | VARKI PAUL | Chief Legal Officer | Sell | 400 | $23.71 | $9K | 4K |
| 2026-05-06 | VARKI PAUL | Chief Legal Officer | Sell | 9K | $22.70 | $210K | 4K |
| 2026-05-06 | VARKI PAUL | Chief Legal Officer | Sell | 23K | $21.22 | $485K | 13K |
| 2026-05-06 | VARKI PAUL | Chief Legal Officer | Sell | 5K | $19.78 | $103K | 36K |
| 2026-05-06 | VARKI PAUL | Chief Legal Officer | Sell | 37K | $18.91 | $707K | 41K |
| 2026-05-06 | VARKI PAUL | Chief Legal Officer | Exercise or conversion | 13K | $8.04 | $101K | 79K |
| 2026-05-06 | VARKI PAUL | Chief Legal Officer | Exercise or conversion | 63K | $13.43 | $839K | 66K |
| 2026-05-05 | Doyle Mittie | Chief Medical Officer | Sell | 2K | $16.00 | $27K | 4K |
| 2026-05-05 | Doyle Mittie | Chief Medical Officer | Exercise or conversion | 679 | $8.04 | $5K | 5K |
| 2026-05-05 | Doyle Mittie | Chief Medical Officer | Exercise or conversion | 1K | $12.65 | $13K | 5K |
| 2026-04-30 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 8K | $13.23 | $112K | 423 |
| 2026-04-29 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 8K | $13.09 | $111K | 9K |
| 2026-04-06 | Doyle Mittie | Chief Medical Officer | Sell | 4K | $18.01 | $72K | 4K |
| 2026-04-06 | Doyle Mittie | Chief Medical Officer | Exercise or conversion | 4K | $12.65 | $50K | 8K |
| 2026-04-02 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 2K | $17.57 | $31K | 17K |
| 2026-04-02 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 6K | $17.02 | $106K | 19K |
| 2026-04-01 | Doyle Mittie | Chief Medical Officer | Sell | 679 | $16.00 | $11K | 4K |
| 2026-04-01 | Doyle Mittie | Chief Medical Officer | Exercise or conversion | 679 | $8.04 | $5K | 4K |
| 2026-04-01 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 7K | $16.83 | $126K | 25K |
| 2026-04-01 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 500 | $15.86 | $8K | 33K |
| 2026-03-28 | Goldman Jonathan | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 3K |
| 2026-03-28 | Chan Mitchell | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 6K |
| 2026-03-28 | Sullivan Christopher Ryan | Chief Financial Officer | Exercise or conversion | 24K | price not stated in the filing | not stated | 42K |
| 2026-03-28 | Sullivan Christopher Ryan | Chief Financial Officer | Tax withholding | 8K | $13.89 | $114K | 33K |
| 2026-03-28 | NEIL GARRY ARTHUR | Chief Executive Officer | Tax withholding | 22K | $13.89 | $304K | 90K |
| 2026-03-28 | NEIL GARRY ARTHUR | Chief Executive Officer | Exercise or conversion | 65K | price not stated in the filing | not stated | 112K |
| 2026-03-28 | KAPLAN GILLA | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 6K |
| 2026-03-28 | KANTOFF AARON | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 6K |
| 2026-03-28 | Truex Samantha | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 6K |
| 2026-03-16 | Doyle Mittie | Chief Medical Officer | Sell | 25K | $16.15 | $412K | 4K |
| 2026-03-16 | Doyle Mittie | Chief Medical Officer | Exercise or conversion | 6K | $8.04 | $48K | 29K |
| 2026-03-16 | Doyle Mittie | Chief Medical Officer | Exercise or conversion | 20K | $12.65 | $247K | 23K |
| 2025-12-10 | Doyle Mittie | Chief Medical Officer | Tax withholding | 1K | $4.10 | $4K | 4K |
| 2025-12-10 | Riley Jennifer | Chief Strategy Officer | Tax withholding | 637 | $4.10 | $3K | 3K |
| 2025-12-10 | VARKI PAUL | Chief Legal Officer | Tax withholding | 1K | $4.10 | $4K | 4K |
| 2025-12-10 | Sullivan Christopher Ryan | Chief Financial Officer | Tax withholding | 155 | $4.10 | $636 | 17K |
| 2025-11-14 | Goldman Jonathan | Director | Sell | 8K | $14.35 | $118K | 0 |
| 2025-11-14 | Goldman Jonathan | Director | Exercise or conversion | 8K | $9.88 | $81K | 8K |
| 2025-11-14 | Goldman Jonathan | Director | Sell | 3K | $14.30 | $45K | 0 |
| 2025-03-28 | NEIL GARRY ARTHUR | Chief Executive Officer | Exercise or conversion | 65K | price not stated in the filing | not stated | 65K |
| 2025-03-28 | NEIL GARRY ARTHUR | Chief Executive Officer | Tax withholding | 18K | $8.46 | $150K | 47K |
| 2025-03-28 | Sullivan Christopher Ryan | Chief Financial Officer | Exercise or conversion | 24K | price not stated in the filing | not stated | 24K |
| 2025-03-28 | Sullivan Christopher Ryan | Chief Financial Officer | Tax withholding | 7K | $8.46 | $62K | 17K |
| 2025-03-28 | Almenoff June Sherie | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 3K |
| 2025-03-28 | KAPLAN GILLA | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 3K |
| 2025-03-28 | KANTOFF AARON | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 3K |
| 2025-03-28 | Truex Samantha | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 3K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON16 Form 144 notices on file for AVTX worth $8.6M at the prices reported; 6 in the last 90 days worth $2.2M. Latest: CHRISTOPHER RYAN SULLIVAN filed on 2026-08-18 to sell 31,031 shares ($622K) from 2026-08-18.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-18 | CHRISTOPHER RYAN SULLIVANOfficer | 31K | $622K | 0.058% | 2026-08-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-17 | MITTIE DOYLEOfficer | 5K | $99K | 0.009% | 2026-08-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-17 | CHRISTOPHER RYAN SULLIVANOfficer | 71K | $1.4M | 0.132% | 2026-08-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-17 | CHRISTOPHER RYAN SULLIVANOfficer | 4K | $75K | 0.007% | 2026-08-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-11 | JENNIFER RILEYOfficer | 3K | $52K | 0.005% | 2026-08-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-10 | MITTIE DOYLEOfficer | 679 | $12K | 0.001% | 2026-08-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-02 | JONATHAN GOLDMANDirector | 43K | $616K | 0.081% | 2026-06-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-07 | CHRISTOPHER SULLIVANOfficer | 19K | $406K | 0.082% | 2026-05-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-06 | MITTIE DOYLEOfficer | 55K | $886K | 0.239% | 2026-05-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-06 | CHRISTOPHER SULLIVANOfficer | 47K | $764K | 0.206% | 2026-05-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-06 | PAUL VARKIOfficer | 93K | $1.5M | 0.407% | 2026-05-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-06 | MITCHELL CHANDirector | 3K | $51K | 0.014% | 2026-05-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-29 | CHRISTOPHER SULLIVANOfficer | 17K | $218K | 0.074% | 2026-04-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-06 | MITTIE DOYLEOfficer | 66K | $1.2M | 0.289% | 2026-04-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-01 | CHRISTOPHER SULLIVANOfficer | 16K | $238K | 0.070% | 2026-04-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-16 | MITTIE DOYLEOfficer | 30K | $467K | 0.163% | 2026-03-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first, 50 of 64 shown. JSON32 holders report 5% or more of AVTX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Abigail P. Johnson at 10.8% of the class (5,737,966 shares), filed 2026-08-07 for an event on 2026-07-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-29 | 13G | Trails Edge Capital Partners, LPinvestment adviser, partnership | 2.8M | 5.2% | 2026-10-22 |
| 2026-10-29 | 13G | Trails Edge Biotechnology Master Fund, LPpartnership | 2.8M | 5.2% | 2026-10-22 |
| 2026-10-29 | 13G | Ortav Yehudaiindividual | 2.8M | 5.2% | 2026-10-22 |
| 2026-08-14 | 13G/Ano. 1 | T. Rowe Price Investment Management, Inc.investment adviser | 4K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | David Johnsonparent holding company, individual | 3.2M | 5.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Caligan Partners LPinvestment adviser, partnership | 3.2M | 5.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Rajeev Shahparent holding company, individual | 3.5M | 6.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | RA Capital Healthcare Fund, L.P.partnership | 3.5M | 6.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | RA Capital Management, L.P.investment adviser, partnership | 3.5M | 6.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Peter Kolchinskyparent holding company, individual | 3.5M | 6.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Deep Track Capital, LPinvestment adviser, other entity | 3.6M | 6.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | David Kroinparent holding company, individual | 3.6M | 6.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Deep Track Biotechnology Master Fund, Ltd.corporation | 3.6M | 6.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Wilmot B. Harkeyparent holding company | 1.9M | 3.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Nantahala Capital Management, LLCinvestment adviser | 1.9M | 3.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Daniel Mackparent holding company | 1.9M | 3.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | LAMPERT MARK Nindividual | 2.8M | 5.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | BVF INC/ILcorporation | 2.8M | 5.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | BVF PARTNERS L P/ILinvestment adviser, partnership | 2.8M | 5.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | BVF GP HOLDINGS LLCother entity | 2.6M | 4.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | BIOTECHNOLOGY VALUE FUND L Ppartnership | 1.5M | 2.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | BVF I GP LLCother entity | 1.5M | 2.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | BVF II GP LLCother entity | 1.1M | 2.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | BIOTECHNOLOGY VALUE FUND II LPpartnership | 1.1M | 2.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | BVF Partners OS Ltd.corporation | 185K | 0.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Biotechnology Value Trading Fund OS LPpartnership | 185K | 0.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Behzad Aghazadehparent holding company, individual | 2.3M | 4.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Avoro Capital Advisors LLCinvestment adviser, other entity | 2.3M | 4.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Affinity Asset Advisors, LLCinvestment adviser, other entity | 2.9M | 5.5% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Michael Choindividual, parent holding company | 2.9M | 5.5% | 2026-06-30 |
| 2026-08-07 | 13G/Ano. 4 | Abigail P. Johnsonindividual | 5.7M | 10.8% | 2026-07-31 |
| 2026-08-07 | 13G/Ano. 4 | FMR LLCparent holding company | 5.7M | 10.8% | 2026-07-31 |
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 2.9M | 5.5% | 2026-06-30 |
| 2026-07-27 | 13G | BlackRock, Inc.parent holding company | 3.4M | 6.5% | 2026-06-30 |
| 2026-07-06 | 13G/Ano. 1 | Millennium Management LLCother entity | 10K | 0.0% | 2026-06-30 |
| 2026-07-06 | 13G/Ano. 1 | Israel A. Englanderindividual | 10K | 0.0% | 2026-06-30 |
| 2026-07-06 | 13G/Ano. 1 | Millennium Group Management LLCother entity | 10K | 0.0% | 2026-06-30 |
| 2026-06-18 | 13G | Robert Egen Atkinsonparent holding company, individual | 5.7M | 9.9% | 2026-06-11 |
| 2026-06-18 | 13G | Michael Kramarzparent holding company, individual | 5.7M | 9.9% | 2026-06-11 |
| 2026-06-18 | 13G | Commodore Capital Master LPpartnership | 5.7M | 9.9% | 2026-06-11 |
| 2026-06-18 | 13G | Commodore Capital LPinvestment adviser, partnership | 5.7M | 9.9% | 2026-06-11 |
| 2026-05-26 | 13G | Steven A. Cohenindividual | 2.7M | 5.2% | 2026-05-22 |
| 2026-05-26 | 13G | Point72 Capital Advisors, Inc.corporation | 2.7M | 5.2% | 2026-05-22 |
| 2026-05-26 | 13G | Point72 Asset Management, L.P.partnership | 2.7M | 5.2% | 2026-05-22 |
| 2026-05-15 | 13G/Ano. 3 | OrbiMed Advisors LLCinvestment adviser | 475K | 2.1% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Arsani Williamparent holding company, individual | 1.7M | 3.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Logos Global Master Fund LPpartnership | 1.7M | 3.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Logos Global Management GP LLCparent holding company, other entity | 1.7M | 3.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Logos Global Management LPinvestment adviser, partnership | 1.7M | 3.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Logos GP LLCparent holding company, other entity | 1.7M | 3.2% | 2026-03-31 |
13F holders
Tracked managers holding AVTX at their latest 13F. JSON4 of the 30 tracked managers held AVTX at their latest 13F, $57.9M in total at quarter-end prices. Point72 Asset Management is the largest at $44.1M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Point72 Asset Management | 2026-06-30 | 2.4M | $44.1M | 0.05% | +1.5M |
| Renaissance Technologies | 2026-06-30 | 357K | $6.6M | 0.01% | +237K |
| Citadel Advisors | 2026-06-30 | 324K | $6.0M | 0.00% | +130K |
| Two Sigma Investments | 2026-06-30 | 67K | $1.2M | 0.00% | +3K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$51.5M of operating cash flow.
- Cash
- $85.4M
- Equity
- $448.7M
- Total assets
- $490.8M
- Shares outstanding
- 53,629,989
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | n/a | -$36.4M | n/a | -0.83 |
| Q1 FY 2026 | 2026-03-31 | n/a | -$19.6M | n/a | -0.98 |
| Q4 FY 2025derived | 2025-12-31 | n/a | n/a | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | $0 | -$30.6M | n/a | -2.19 |
| Q2 FY 2025 | 2025-06-30 | n/a | -$20.8M | n/a | -1.92 |
| Q1 FY 2025 | 2025-03-31 | n/a | -$13.1M | n/a | -1.25 |
| Q4 FY 2024derived | 2024-12-31 | $192K | n/a | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | $249K | $23.0M | 9251.8% | -2.83 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $59K | -$78.3M | -$51.5M | n/a | n/a | n/a |
| FY 2024 | 2024-12-31 | $441K | -$35.1M | -$49.1M | n/a | n/a | n/a |
| FY 2023 | 2023-12-31 | $1.9M | -$31.5M | -$30.7M | n/a | n/a | n/a |
| FY 2022 | 2022-12-31 | $18.1M | -$41.7M | -$26.8M | $95K | n/a | n/a |
| FY 2021 | 2021-12-31 | $5.4M | -$84.4M | -$70.9M | $113K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-03 from the cover page.
What this page is
Avalo Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Avalo Therapeutics (AVTX), SEC CIK 1534120, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-02.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-18.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-29.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-16.JSON and CSV
- Company record
- EDGAR filing index for CIK 1534120Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of AVTX is sold short?
11,963,625 shares were held short at the 2026-10-15 settlement, 13.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is AVTX's daily short volume?
On 2026-11-02, 372,008 of the 669,243 AVTX shares reported to FINRA were sold short, 55.6% of the day's reported volume. Short volume is a flow for one day, not a position.
Does AVTX have fails to deliver?
The SEC's latest file shows 188 AVTX shares failed to deliver at settlement 2026-10-02. Fails are reported per settlement date and published twice a month with a lag.
Are AVTX insiders buying or selling?
Insiders at AVTX reported 9 open-market sells worth $1.9M in the last 90 days and no open-market buys. Latest filing: Sullivan Christopher Ryan (Chief Financial Officer) on 2026-09-16.
Have AVTX insiders filed to sell?
16 Form 144 notices on file for AVTX worth $8.6M at the prices reported; 6 in the last 90 days worth $2.2M. Latest: CHRISTOPHER RYAN SULLIVAN filed on 2026-08-18 to sell 31,031 shares ($622K) from 2026-08-18.
Who owns 5% or more of AVTX?
32 holders report 5% or more of AVTX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Abigail P. Johnson at 10.8% of the class (5,737,966 shares), filed 2026-08-07 for an event on 2026-07-31.
What did AVTX report last quarter?
In FY 2025 it generated -$51.5M of operating cash flow.
Which tracked 13F managers own AVTX?
4 of the 30 tracked 13F managers held AVTX shares at their latest filing, $57.9M in all. The largest: Steve Cohen's Point72 Asset Management (2.4M shares, $44.1M), Renaissance Technologies (357K shares, $6.6M), Ken Griffin's Citadel Advisors (324K shares, $6.0M), Two Sigma Investments (67K shares, $1.2M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.